Key takeaways
Rituxan (rituximab) and Remicade (infliximab) are both medications used to treat autoimmune conditions, but they work in different ways and treat different conditions. Rituxan (rituximab) is a monoclonal antibody that targets B cells and is used for certain blood cancers and autoimmune diseases like rheumatoid arthritis and pemphigus vulgaris. It is given as an intravenous infusion, often requiring premedications to prevent infusion-related reactions. Remicade (infliximab), on the other hand, is a biologic DMARD that blocks tumor necrosis factor (TNF) to reduce inflammation and is used for conditions like Crohn's disease, ulcerative colitis, and severe plaque psoriasis. Remicade (infliximab) is also administered via IV infusion but typically requires less frequent dosing compared to Rituxan (rituximab). While both medications can increase the risk of infections, Remicade (infliximab) has additional warnings for potential cancer risks and liver problems. Rituxan and Remicade are both available as brand-name medications, which can be more expensive. They also each have biosimilar products, which may cost less.
